MeiraGTx (Nasdaq: MGTX), a pioneering genetic medicine company renowned for its innovative approach to treating some of the most pressing health challenges, has successfully raised $30 million in its latest funding round. This significant infusion of capital underscores the company's commitment to advancing its robust pipeline of late-stage clinical programs, which are bolstered by its end-to-end manufacturing capabilities. MeiraGTx boasts an internally developed manufacturing platform that includes two Good Manufacturing Practice (GMP) viral vector production facilities, enabling the company to streamline production processes from plasmid generation to final product release. The funding will primarily support the further development of MeiraGTx's transformative riboswitch platform technology, which allows for precise, dose-responsive control of gene expression via oral small molecules. By focusing on the delivery of metabolic peptides such as GLP-1, GIP, Glucagon, and PYY, MeiraGTx aims to revolutionize treatment options for diseases with significant unmet needs, including conditions affecting the eye, central nervous system, and salivary glands. Beyond these initial targets, MeiraGTx is also set to expand its technology applications, addressing more widespread diseases and optimizing therapies for oncology and autoimmune disorders. As the company continues to innovate and scale its capabilities, this funding puts MeiraGTx in an even stronger position to transform the landscape of genetic medicine and ultimately improve patient outcomes across diverse therapeutic areas.
MeiraGTx Secures $30 Million in Funding for Genetic Medicine Advancements
Recently funded 路 $30.0MGenetic Medicine
Get the full MeiraGTx company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
